At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTC Benitec Biopharma
Pre-Mkt 06-18 05:14:52 EDT
11.80
+0.70
+6.31%
盘前11.85
+0.05+0.42%
04:00 EDT
High12.03Low10.86Vol152.20K
Open11.04D1 Closing11.10Amplitude10.54%
Mkt Cap404.21MTradable Cap246.04MTotal Shares34.25M
T/O1.79MT/O Rate0.73%Tradable Shares20.85M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim
TIPRANKS  ·  06-10
Benitec Biopharma downgraded to Neutral from Buy at Guggenheim
Benitec Biopharma Announces Board Changes and New Director
TIPRANKS  ·  05-30
Benitec Biopharma Announces Board Changes and New Director
BRIEF-Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026
Reuters  ·  05-30
BRIEF-Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026
Benitec Biopharma - Megan Boston to Continue as Chief Financial Officer and Secretary - SEC Filing
THOMSON REUTERS  ·  05-30
Benitec Biopharma - Megan Boston to Continue as Chief Financial Officer and Secretary - SEC Filing
Benitec Biopharma files Form 3 for director David Matthew Friedman
Reuters  ·  05-29
Benitec Biopharma files Form 3 for director David Matthew Friedman
Benitec Biopharma posts BB-301 gene therapy update for OPMD-related dysphagia
Reuters  ·  05-16
Benitec Biopharma posts BB-301 gene therapy update for OPMD-related dysphagia
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  05-15
Calendar of U.S. Earnings Expected in the Week Ahead
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
TIPRANKS  ·  05-15
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-14
Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate
Benzinga  ·  05-14
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate
Benitec Biopharma Q3 net loss narrows as expenses fall
Reuters  ·  05-14
Benitec Biopharma Q3 net loss narrows as expenses fall
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
THOMSON REUTERS  ·  05-14
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Inc - Cash and Cash Equivalents $184.8 Mln as of March 31, 2026
THOMSON REUTERS  ·  05-14
Benitec Biopharma Inc - Cash and Cash Equivalents $184.8 Mln as of March 31, 2026
Benitec Biopharma Inc - on Track to Engage With FDA Mid-Year to Formalize Bb-301 Pivotal Study Design
THOMSON REUTERS  ·  05-14
Benitec Biopharma Inc - on Track to Engage With FDA Mid-Year to Formalize Bb-301 Pivotal Study Design
Benitec Biopharma Q3 Operating Income USD -13.6 Million
THOMSON REUTERS  ·  05-14
Benitec Biopharma Q3 Operating Income USD -13.6 Million
Benitec Biopharma initiated with an Outperform at Evercore ISI
TIPRANKS  ·  05-12
Benitec Biopharma initiated with an Outperform at Evercore ISI
Benitec Biopharma Initiated at Outperform by Evercore ISI Group
Dow Jones  ·  05-12
Benitec Biopharma Initiated at Outperform by Evercore ISI Group
Benitec Biopharma Inc expected to post a loss of 27 cents a share - Earnings Preview
Reuters  ·  05-08
Benitec Biopharma Inc expected to post a loss of 27 cents a share - Earnings Preview
Benitec to present interim Phase 1b/2a BB-301 OPMD trial results at ASGCT meeting
Reuters  ·  04-28
Benitec to present interim Phase 1b/2a BB-301 OPMD trial results at ASGCT meeting
Benitec Biopharma to host MDA conference industry forum breakfast on BB-301 OPMD trial results
Reuters  ·  03-10
Benitec Biopharma to host MDA conference industry forum breakfast on BB-301 OPMD trial results

Introduction

Company Name.
Benitec Biopharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Issue price:
--